Highlights Chimerix, Inc. Börse Stuttgart

Equities

CXF

US16934W1062

Market Closed - Börse Stuttgart Other stock markets 09:00:48 05/07/2024 BST			5-day change	1st Jan Change
0.819 ^EUR	+4.33%		+0.12%	+0.54%

05-01	Transcript : Chimerix, Inc., Q1 2024 Earnings Call, May 01, 2024
05-01	Chimerix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Chimerix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Earnings Flash (CMRX) CHIMERIX Reports Q4 Revenue $4,000, vs. Street Est of $70,000	02-29	MT
Earnings Flash (CMRX) CHIMERIX Posts Q3 Revenue $11,000, vs. Street Est of $90,000	11-02	MT
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery	16/08/23	CI
Earnings Flash (CMRX) CHIMERIX Posts Q2 Revenue $26,000, vs. Street Est of $270,000	03/08/23	MT
Chimerix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Earnings Flash (CMRX) CHIMERIX Reports Q1 Revenue $283,000, vs. Street Est of $130,000	04/05/23	MT
Chimerix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/03/23	CI
Earnings Flash (CMRX) CHIMERIX Posts Q4 Revenue $814,000, vs. Street Est of $580,000	02/03/23	MT
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	02/03/23	CI
Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study	08/12/22	CI
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI
Earnings Flash (CMRX) CHIMERIX Reports Q3 Revenue $32.6M	03/11/22	MT
Emergent BioSolutions Completes Acquisition of Rights to Smallpox Oral Antiviral Tembexa	26/09/22	MT
Emergent BioSolutions Inc. completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. for approximately $370 million.	25/09/22	CI
Chimerix Chief Business Officer Michael Andriole Executes Purchase of 50,000 Shares	29/08/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Chimerix, Inc. Börse Stuttgart

Equities

CXF

US16934W1062

Highlights

Filters